Revival Takes Root: Avantor's Return to Growth Begins to Show Up in the Numbers
The +83% 90-day tape is starting to be validated by Q2 results — VWR is growing again, orders lead BMP's inflection, and leverage heads below 3x.
AVTR · Earnings Call · 2026-07-29
The Turnaround Trade Has Already Moved
Avantor's tape tells a remarkable story even before a word of this call is read: the stock is up 83% over the trailing 90 days, a violent reversal for a name that spent three years grinding down 67% from its September 2021 peak. Yet after that run, the valuation still reflects deep skepticism. Price-to-revenue sits at just 0.8x, well below the 2-3x range of 2021-2022. The market is pricing an inflection, not a conclusion.
CEO Emmanuel Ligner, now approaching a year in the seat, has anchored the story in Revival, a five-pillar program encompassing commercial excellence, operational performance, portfolio optimization, simplification, and talent — and he's explicit that he wants self manufacturing optionality preserved inside the distribution model. His opening message this quarter was unambiguous:
We remain highly focused on executing Revival, and I am very happy with the progress we made to date. Revival delivered measurable results and put us on a path to sustainable growth.
VWR: Return to Growth — Whose Credit?
The headline datapoint is the VWR distribution segment's return to positive organic growth: 1.7% in Q2, versus -4.8% in Q1. Management attributes the swing primarily to deliberate actions — the vwr.com relaunch, stronger performance with large global customer accounts as contract-renewal comparisons ease, and e-commerce gains among smaller, higher-margin customers.
Pressed on whether this is execution or a recovering market, Emmanuel was direct: “more than half of the growth that we deliberated in Q2 comes from deliberated action” — Emmanuel Ligner, President and Chief Executive Officer · 2026-07-29. The e-commerce platform is the most tangible artifact — a relaunched site driving direct traffic, higher conversion, and accelerating daily sales, particularly in Europe where the digital roadmap is still early.
This represents a clear tonal shift from the April call, when management was still characterizing Q1 as “the tail of those market share loss” — Emmanuel Ligner, President and Chief Executive Officer · 2026-04-29 and emphasizing stabilization. Steve Eck's acknowledgement keeps expectations honest:
While the 1.7% growth is not quite yet market, I just want to highlight that we moved from negative 4.8% in 1Q to positive 1.7% in 2Q, and we expect that growth rate to continue to accelerate here as we get into the second half.
The trajectory — negative 4.8% to positive 1.7% with faster growth guided for H2 — is the direction the board has been waiting for. Unsurprisingly, return to growth has surged to the #2 keyword in the company's quarterly trajectory.
BMP Orders Lead the Next Inflection
The cleaner leading indicator sits in Bioscience & Medtech Products. Revenue was still down 5.6% organically, but that figure masks ~600 basis points of discrete headwinds — NuSil and Serum ordering normalization plus Fluid Handling's difficult comparison. CFO Steve Eck sized the drag: adjusted operating margin in BMP fell year-over-year on lower volumes, though it improved sequentially.
The order book, however, tells a more constructive story, and it's building on prior quarters' evidence. From the April call, the same dynamic was already visible — with the confidence that “60 days, 90 days” — Emmanuel Ligner, President and Chief Executive Officer · 2026-04-29 lead times would convert orders into second-half revenue. Now it's confirmed across the full first half:
“from the first half, it's the same. It's low double-digit order book for the entire first half, which is, I think, very encouraging.” — Emmanuel Ligner, President and Chief Executive Officer · 2026-07-29
With the discrete drag set to shrink to ~150bps in Q3 and ~400bps in Q4 (Electronic Materials), the arithmetic for a BMP return to growth in the back half — and durable growth in 2027 — is much more grounded than it was a year ago. Emmanuel closed the door on hedging about next year: “we will exit '26 with momentum... I'm confident and optimistic that 2027 will be a growth year” — Emmanuel Ligner, President and Chief Executive Officer · 2026-07-29.
The Balance Sheet Carries the Credibility
Free cash flow is Avantor's quiet strength. Ex-restructuring, Q2 generated $152M, funding $112M of debt repayment, with ~$500M repaid over the trailing twelve months. Effective net cash improved to -$3.55B, and adjusted net leverage is 3.3x. The stated goal is below 3x by fiscal year-end, supported by a Moody's outlook upgrade to positive and a July term-loan repricing. The leverage ratio keyword now ranks in the top 10 of the company's trajectory — a sign the balance-sheet narrative is central to this report.
The margin hole, though, remains the stubborn problem. Gross margin sits at 31.7%, down 2.2 points year-over-year; the operating margin picture is far more dramatic: down 3.0 points to 6.3% versus a 16.2% peak two quarters ago. This is a volume-led recovery — the company needs top-line flow to absorb fixed costs, and management flagged inflationary pressure and freight costs as continuing headwinds. Interest coverage, at 2.3x, underscores why deleveraging matters so much to the equity story.
None of this is a done deal. The fundamentals as of the April period still showed revenue flat, net income down 33%, and FCF down 76% year-over-year. But the order books, the VWR inflection, the e-commerce flywheel, and the deleveraging trajectory are all now moving the same direction — and the 90-day tape suggests investors are starting to believe it.